Citations

Clear

4510 citation(s) found for "Scott, C".

Genotype-specific communication profiles in 79,518 individuals with neurodevelopmental disorders
Hsu, Cristiane , Ivaniuk, Alina , Jiménez-Gómez, Andrés , Brünger, Tobias , Perry, M. Scott, Phan, Chiara, Arenivas, Ana, Oyler, Haley O. , Lal, Dennis , Bruenger, Tobias , Bosselmann, Christian , Perry, Michael Scott , Arenivas, Ana , Oyler, Haley O , Leu, Costin , Ivaniuk, Alina , Boßelmann, Christian M. , Ludwig, Natasha N. , Leu, Costin

Mayo Clinic

No container title available | February 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.03.26345484 | PMID 41674637 Get It

Abstract Rationale Neurodevelopmental disorders (NDDs) are characterised by significant challenges in communication, social interaction, and adaptive function, often impacting quality of life. Previous studies support genetic influences on the communication abilities of individuals with NDD, but were either limited to single genetic conditions or to small cohorts with a limited selection of communication measures. Methods We analysed caregiver-reported communication abilities in 79,518 individuals with NDD from the Simons Searchlight and SPARK registries: 4,439 with a CNV-based or monogenic NDD and 75,079 with autism spectrum disorder (ASD) without a known genetic cause (idiopathic ASD) as controls. For analysis, we a priori selected 10 communication-related measures based on their availability in the study cohorts, coverage of distinct communication aspects, and their frequent use in neurodevelopmental phenotyping, yielding 177,328 data points across all study cohorts. The individuals in the Searchlight registry were divided into a Discovery cohort (the 15 most prevalent genetic NDD conditions) and a Confirmation cohort (all other genetic NDD conditions). A second Confirmation cohort was generated using all individuals with genetic ASD forms from the SPARK registry. We then tested each of the three case cohorts and each genetic condition represented in the Discovery cohort against the ASD control cohort. Developmental trajectories were assessed through testing of participants grouped by age at evaluation. Results Measure-level analyses demonstrated significant associations between genetic status and communication abilities, differences in communication abilities between classes of genetic variants (monogenic vs. CNV-based NDDs), and variability between specific genetic NDD conditions. CNV-based NDDs showed milder communication impairment, outperforming idiopathic ASD controls in 9/10 communication measures, whereas monogenic NDD conditions had more pervasive impairments, especially in verbal communication. Although impaired in verbal communication, five monogenic NDD conditions showed at least suggestive strengths in nonverbal and social communication relative to idiopathic ASD controls ( CSNK2A1 , CTNNB1 , SETBP1 , MED13L , and PPP2R5D ), specifically in using gestures. Developmental trajectory analyses revealed STXBP1 as the gene group at highest risk of developmental stagnation in communication abilities. Conclusions These findings underscore the potential of precision speech-language pathology (SLP) approaches tailored to the specific verbal and nonverbal communication strengths and weaknesses of genetic groups. We also provide evidence for measurable improvements and declines in communication abilities with age at the group level, highlighting the need for developmentally informed care. By integrating genetic insights into clinical practice, precision SLP approaches may enhance communication outcomes and developmental progress and improve quality of life for individuals with genetic NDDs.
Artificial Intelligence–Electrocardiography to Predict Incident Atrial Fibrillation and Clinical Outcomes in Kidney Transplant Recipients
Scalia, Isabel G., Farina, Juan M., Abdelnabi, Mahmoud H., Pietri, Milagros Pereyra, Ibrahim, Ramzi, Awad, Kamal, Abbas, Mohammed Tiseer , Ali, Nima Baba , Mahmoud, Ahmed K., Steidley, D. Eric, Masry, Hicham El , Sorajja, Dan , Scott, Luis R., Lee, Kwan, Johnson, D. W., Riad, Samy M. , Lester, Steven J., Jk, Oh, Ayoub, Chadi, Arsanjani, Reza, Farina, Juan M. , Ibrahim, Ramzi , Scalia, Isabel G. , Scalia, Isabel G , Farina, Juan M , Pereyra Pietri, Milagros, Pathangey, Girish , Ibrahim, Ramzi , Tiseer Abbas, Mohammed, Baba Ali, Nima , Alsidawi, Said , El Masry, Hicham , Sorajja, Dan , Scott, Luis R , Lee, Kwan S , Cho, Yeoungjee , Johnson, David W , Wadei, Hani M , Chao, Chieh-Ju , Mour, Girish K , Arsanjani, Reza , Abbas, Mohammed Tiseer , Pereyra, Milagros , Pathangey, Girish , Awad, Kamal , Mahmoud, Ahmed , Alsidawi, Said , Steidley, D. Eric , Scott, Luis R. , Cho, Yeoungjee , Wadei, Hani M. , Chao, Chieh‐Ju , Mour, Girish , Arsanjani, Reza

Mayo Clinic

Kidney360 | February 4, 2026 | Volume: 7 | Issue: 5 | Pages: 1128-1140

10.34067/kid.0000001063 | PMID 41637137 Get It

Key Points Atrial fibrillation after kidney transplantation is common and is associated with poor prognosis. Artificial intelligence applied to 12-lead electrocardiograms pretransplant accurately predicts the risk of new-onset atrial fibrillation in our cohort. High-risk artificial intelligence electrocardiography score was independently associated with increased risk of mortality and allograft failure. Background Incident atrial fibrillation (AF) is common after kidney transplantation (KTx) and is associated with worse clinical outcomes. Artificial intelligence electrocardiography (AI-ECG) algorithms have demonstrated efficacy in predicting risk of new-onset AF in the general population; however, their prognostic value in KTx recipients is relatively unknown. Methods Retrospective analysis was conducted on KTx recipients without AF, with at least one pretransplant ECG between 2011 and 2021 across three tertiary centers in the United States (Mayo Clinic sites in MN, AZ, and FL). A previously validated AI-ECG algorithm estimated the probability of incident AF for each patient. Based on AI-ECG probabilities, patients were categorized into high-risk and low-risk groups, with the optimal AI-ECG score cutoff determined. The incidence of new-onset AF, allograft failure, and mortality was compared between groups. Results Overall, 6246 patients (age 53.5±13.8 years; 58.9% male) were included. Pretransplant AI-ECG probability of AF ≥5% was the optimal cutoff for high risk of incident AF (sensitivity 72%, specificity 62%). High-risk scores were associated with true new-onset AF at 30 days (adjusted hazard ratio [aHR], 2.89; 95% confidence intervals [CI], 2.05 to 4.09; P < 0.001), 3 years (aHR, 2.54; 95% CI, 1.99 to 3.26, P < 0.001), and 5 years post-transplant (aHR, 2.48; 95% CI, 1.99 to 3.09, P < 0.001). High-risk AI-ECG scores were also associated with increased mortality (aHR, 1.56; 95% CI, 1.30 to 1.88, P < 0.001) and overall allograft failure (aHR, 1.50; 95% CI, 1.30 to 1.75, P < 0.001) through the 5-year follow-up. Conclusions This pretransplant AI-ECG parameter identified patients at increased risk of new-onset AF post-KTx and provided prognostic utility. Overall, this easy to obtain tool allows for risk stratification of patients who may benefit from closer monitoring, targeted risk factor modification, and early intervention.
Direct oral anticoagulants versus warfarin for atrial fibrillation in patients with transthyretin cardiac amyloidosis: a retrospective cohort analysis
Habib, Eiad, Ibrahim, R, Abdelnabi, M, Pham, N, Masry, H El, Rosenthal, J, Steidley, Eric, Scott, L, Sorajja, Dan , Ayoub, C, Arsanjani, R, Habib, Eiad , Abdelnabi, Mahmoud , Farina, Juan M. , Masry, Hicham El , Arsanjani, Reza

Mayo Clinic

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.509 Get It

Abstract Background/Introduction Patients with transthyretin cardiac amyloidosis (ATTR-CA) and atrial fibrillation (AF) have increased risk for left atrial thrombi, necessitating anticoagulation therapy if bleeding risk is not prohibitive. Limited data is available comparing the use of direct oral anticoagulants (DOACs) to warfarin in this population. Purpose To evaluate and compare clinical efficacy and safety outcomes of DOACs versus warfarin in patients with ATTR-CA and AF. Methods We conducted a retrospective cohort study using the TriNetX Network, which includes data from over 140 million patients, between 2014 and 2022. Adults (aged ≥18 years) with ATTR-CA and AF were identified. These patients were further categorized into two groups: one cohort which utilized DOACs for oral anticoagulation and the other cohort on warfarin. 1:1 propensity score matching (PSM) was utilized to balance baseline characteristics between the two cohorts. The primary outcome was rate of stroke, with secondary outcomes including all-cause death, all-cause hospitalizations, and acute heart failure exacerbations. Safety outcomes included intracranial hemorrhage, gastrointestinal hemorrhage, and hematuria. Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) were calculated. Results Among 8,214 adults with ATTR-CA and AF, 5,774 patients were on a DOAC while 2,440 patients were on warfarin. After PSM, 2,425 patients were included in each group. The use of DOACs for AF in patients with ATTR-CA was associated with a significantly lower risk of ischemic stroke compared to warfarin (5.7% versus 7.3%, aOR 0.771 [95% CI, 0.612-0.971]) by the end of the one year follow up. There were no differences in all-cause mortality (19.8% versus 21%, aOR 0.927 [95% CI, 0.806-1.066]), all-cause hospitalizations (19.2% versus 21.6%, aOR 0.863 [95% CI, 0.624-1.195]) or heart failure exacerbations (43.6% versus 46%, aOR 0.906 [95% CI, 0.809-1.015]). Safety outcomes favored DOACs over warfarin, with a lower risk of intracranial hemorrhage (4.5% versus 7.8%, aOR 0.565 [95% CI, 0.444-0.720]), and comparable rates of GI hemorrhage and hematuria. Conclusions DOACs may be safely used in ATTR-CA patients with AF, offering a lower risk of stroke compared to warfarin and a more favorable safety profile. These findings emphasize the potential advantages of DOACs in this population and underline the need for prospective studies to validate these results.
Characterizing early behavioral and social–emotional problems in young children with SCN1A + Dravet syndrome: Findings from the E
Scheffer, Ingrid E., Perry, M. Scott, Sullivan, Joseph , Boronat, Susana , Wheless, J. W., Brunklaus, Andreas , Laux, Linda C, Patel, Anup D. , Roberts, Colin, Dlugos, Dennis J., Holder, Deborah , Lallas, Matt, Phillips, Steven, Segal, Eric , Lal, Dennis , Wirrell, Elaine, Zuberi, Sameer M., Shaffer, Rebecca, Wojnaroski, Mary , Christensen, Sarah , James, Emma S., Huang, Norman, Gofshteyn, Jacqueline S. , Scheffer, Ingrid E. , Wheless, James W. , Shaffer, Rebecca C. , Scheffer, Ingrid E , Perry, Michael Scott , Wheless, James W , Dlugos, Dennis , Knupp, Kelly G , Phillips, Steven , Segal, Eric , Lal, Dennis , Wirrell, Elaine C , Zuberi, Sameer M , Shaffer, Rebecca , Wojnaroski, Mary , Berl, Madison , James, Emma S , Vila, Maria Candida , Gofshteyn, Jacqueline S , Rico, Salvador , Patel, Anup D , Brunklaus, Andreas , Laux, Linda , Roberts, Colin, Dlugos, Dennis , Knupp, Kelly G. , Phillips, Steven , Wirrell, Elaine , Zuberi, Sameer M. , Berl, Madison M. , James, Emma S. , Huang, Norman, Rico, Salvador

Mayo Clinic

Epilepsia | February 2, 2026 | Volume: 67 | Issue: 5 | Pages: 2463-2479

10.1002/epi.70127 | PMID 41627953 Get It

Abstract Objective Dravet syndrome (DS) is the prototypic developmental and epileptic encephalopathy, characterized by drug‐resistant seizures, developmental slowing, and many other morbidities. Detailed characterization of behavioral phenotypes and social–emotional skill development are limited. Methods We prospectively assessed behavioral and social–emotional problems in the ENVISION natural history study (NCT04537832) of children with DS associated with SCN1A pathogenic variants ( SCN1A + DS) enrolled at <5 years of age. Assessments every 3 months for up to 2 years included the Child Behavior Checklist (CBCL), Strengths and Difficulties Questionnaire (SDQ), Brief Infant‐Toddler Social and Emotional Assessment (BITSEA), and Vineland Adaptive Behavior Scales, 3rd Edition (VABS‐3). Results Fifty‐eight children with DS enrolled at 16 sites worldwide. Problematic behaviors—inattention, aggressive or oppositional behaviors, and withdrawn and autistic behaviors—began before age 3 years, became more evident with age, and were clinically significant in many children by age 3–4 years. CBCL Total, Externalizing, and Internalizing Problems T‐scores rose by approximately 3 points per year, and BITSEA Problem scale scores increased by 2.3 points annually ( p = .002). SDQ Hyperactivity scores worsened over time ( p = .013), whereas emotional difficulties remained stable. VABS‐3 Socialization domain scores, which were already more than 1 SD below the normative mean at baseline, decreased further, particularly in younger participants. Correlation analyses showed that poorer communication abilities were associated with increased problematic behaviors ( R = −.55 for CBCL Total Problems and VABS‐3 Communication scores). Mixed‐effects modeling identified age as the strongest predictor of worsening behavioral outcomes. Significance We found that behavioral and social–emotional problems are inherent components of DS that present in toddlerhood and worsen throughout early childhood. This highlights the need to diagnose and manage these issues early. Targeted therapy may alleviate the wide‐ranging morbidities that are intrinsic to DS, including the social–emotional and behavior problems that frequently emerge.
Blood Pressure Variability (BPV) as a Novel Digital Biomarker of Multisystem Risk and Diagnostic Insight: Measurement, Mechanisms, and Emerging Artificial Intelligence Methods
Pugalenthi, Lakshmi Sree , Senapati, Sidhartha Gautam , Gohri, Jay , Anam, Hema Latha, Madan, Hritik, Arora, Adi , Arora, Avni, LEE, JIEUN , Yerrapragada, Gayathri, Elangovan, Poonguzhali, Shariff, Mohammed Naveed , Natarajan, T.K. , Janarthanan, Jayarajasekaran, Agarwal, Shreshta, Karuppiah, Shiva Sankari, Sood, Divyanshi, Rapolu, Swetha, Iyer, Vivek, Helgeson, Scott A. , Arunachalam, Shivaram P. , Iyer, Vivek , Elangovan, Poonguzhali , Elangovan, Poonguzhali , Natarajan, Thangeswaran , Agarwal, Shreshta , Iyer, Vivek N , Arunachalam, S P , Helgeson, Scott A , Shariff, Mohammad Naveed , Yerrapragada, Gayathri

Mayo Clinic

Biomedicines | January 30, 2026 | Volume: 14 | Issue: 2 | Pages: 317

10.3390/biomedicines14020317 | PMID 41751215 Get It

Hypertension has been traditionally known to be highlighted by mean blood pressure; however, emerging evidence exhibits that blood pressure variability (BPV), including short-term, day-to-day, and visit-to-visit fluctuations can have an implication across multiple body systems. Elevated BPV reflects repetitive hemodynamic stress, affecting the physiologic hemostasis contributing to vascular injury and end organ damage. This narrative review is a compilation of recent evidence on the prognostic value of BPV, explained by pathophysiology, various devices with its measurement approaches, and, essentially, the clinical implication of BPV and the use of such devices utilizing artificial intelligence. A comprehensive literature search across PubMed, Cochrane Library, Scopus, and Web of Science were conducted, focusing on observational studies, cohorts, randomized trials, and meta-analyses. Higher BPV has been associated with an increased risk of cardiovascular mortality, stroke, coronary events, and heart failure, the progression of chronic kidney disease, cognitive decline, and preeclampsia, among other end organ damage, despite mean blood pressure. The various pathophysiologic mechanisms include autonomic dysregulation, arterial stiffness, endothelial dysfunction, circadian rhythm alteration, and systemic inflammation, which result in vascular remodeling and multisystem damage. Antihypertensive medications such as calcium channel blockers and renin–angiotensin–aldosterone system inhibitors seem to reduce BPV; randomized trials have not specifically investigated their BPV-reducing effects. The aim of this review is to highlight that BPV is a dynamic marker of multisystem risk, and question how various AI-based devices can aid continuous BPV monitoring and patient specific risk stratification.
Relationship between age and severity of cognitive impairment at diagnosis for early‐onset and late‐onset Alzheimer's disease: Comparison of LEADS and ADNI
Hammers, Dustin B., Eloyan, Ani, Thangarajah, Maryanne, Taurone, Alexander, Gao, Sujuan, Beckett, Laurel, Kirby, Kala, Dage, Jeffrey L., Nudelman, Kelly, Aisen, Paul, Reman, Rema, Vemuri, Prashanthi, Joie, Renaud La, Touroutoglou, Alexandra, Atri, Alireza, Clark, David, Day, Gregory S., Duara, Ranjan, Graff‐Radford, Neill R., Honig, Lawrence S., Jones, D., Masdeu, Joseph C. , Mendez, Mario F., Womack, Kyle, Musiek, Erik, Onyike, Chiadi U., Riddle, Meghan, Grant, Ian, Rogalski, Emily, Johnson, Erik C. B., Salloway, Steven, Sha, Sharon J. , Turner, Raymond Scott, Wingo, Thomas S., Wolk, David A., Carrillo, Marı́a C., Dickerson, Bradford C., Rabinovici, Gil D., Apostolova, Liana G., Initiative, for the Alzheimer's Disease Neuroimaging, Carrillo, María C. , Rabinovici, Gil D. , Joie, Renaud La , Day, Gregory S. , Day, Gregory S , La Joie, Renaud , Rabinovici, Gil D , Hammers, Dustin B , Eloyan, Ani , Taurone, Alexander, Gao, Sujuan , Beckett, Laurel , Dage, Jeffrey L. , Nudelman, Kelly , Aisen, Paul , Reman, Rema, Vemuri, Prashanthi , Touroutoglou, Alexandra , Atri, Alireza , Clark, David, Duara, Ranjan , Graff‐Radford, Neill R. , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Mendez, Mario F. , Musiek, Erik , Onyike, Chiadi U. , Riddle, Meghan , Johnson, Erik C. B. , Salloway, Steve , Turner, Raymond Scott , Wolk, David A. , Dickerson, Bradford Clark , Apostolova, Liana G. , Initiative, for the Alzheimer’s Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | January 30, 2026 | Volume: 22 | Issue: 2 | Pages: No page available

10.1002/alz.71160 | PMID 41614286 Get It

INTRODUCTION Recent work has identified unique cognitive profiles for early‐onset Alzheimer's disease (EOAD) relative to late‐onset Alzheimer's disease (LOAD), however, examination has been limited in determining whether the association between age and cognitive severity at presentation also differs across conditions. METHODS A series of linear spline regression models was conducted across baseline cognitive data from 325 EOAD and 314 LOAD participants, after accounting for education, sex, and apolipoprotein ε4 status. RESULTS Significant differences existed in the relationship between baseline age and cognitive performance between EOAD and LOAD samples for Processing Speed/Attention, Executive Functioning, and Episodic Immediate Memory. Younger participants from both EOAD and LOAD groups performed disproportionately worse on non‐amnestic cognitive domains, with this occurring to a greater extent in EOAD than LOAD. DISCUSSION In the age of disease‐modifying treatments, results highlight the importance of assessing for cognitive declines in individuals starting much earlier than age 65. Highlights Early‐onset Alzheimer's disease (EOAD) and late‐onset Alzheimer's disease (LOAD) participants each displayed cognitive impairments relative to same‐aged peers across most domains. Both groups displayed positive relationships between impairment among non‐amnestic cognitive domains and baseline age. This relationship displayed a significantly greater effect in EOAD than LOAD, with domains of Processing Speed/Attention and Executive Functioning skills being the most pronounced. Of those participants developing AD, age displayed a disproportionate impact on their symptom onset.
Abstract WP208: Strategic Regionalization of Stroke Transfers: Enhancing Patient-Centered Care Through Telestroke Networks
Miller, Blake, Petrone, Ashley , Findley, Scott , Mandel, Daniel M, Burkhardt, Lucas, Coevering, Russell J. Van , Adcock, Amelia

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.wp208 Get It

Background: Interfacility transfers, especially in rural settings, present challenges including limited ambulance availability, bed capacity, image sharing and disparities in access. Regional transfer minimizes time to definitive stroke center care, relies less on costly helicopter transport, supports local healthcare economies, and preserves comprehensive stroke center (CSC) resources for those most likely to benefit. Although these advantages are well-established and reflected in the guidelines, transfers within our connected care rural network were not previously accepted at hospitals outside of our central comprehensive stroke center (CSC). Methods: We identified a local primary stroke center to serve as the regional stroke transfer center (rSTC) within our larger telestroke network. Over one year, (2023-2024), stakeholder meetings with representatives from the rSTC, surrounding smaller hospitals and the CSC were conducted to pinpoint potential roadblocks and create workflows that facilitated regional transfer. Regionally appropriate transfers were defined as patients without LVO, low likelihood for any neurosurgical decompression, or critical illness requiring dedicated neuro-intensive care. Education surrounding these criteria occurred quarterly and case logs were maintained and reviewed by the rSTC stroke coordinator. Retrospective chart review one year following the intervention period (2024-2025) was performed. Results: Of the 99 total transferred patients, 73 (73.7%) patients were transferred regionally. Their average LOS was 2.1 days, with 0% mortality rate and 0% requiring a secondary transfer to the CSC. 26 (26.3%) patients went to the CSC; LOS was 10.6 days and mortality 23.1%. Transfer times were shorter for rSTC patients (60 min vs 188 min). Six CSC patients met regional criteria (26.3% overtriage rate). Conclusion: Establishing an effective regional transfer model is possible with broad stakeholder engagement and regular network maintenance. Following our intervention, most eligible patients remained local and were treated appropriately. Although there was a significant reduction of the patients transferred to the CSC, the majority of CSC transfers were also appropriately triaged. This rSTC model facilitates the care of all stroke patients by providing the right level of care for the right patient, avoiding futile transfers with costly admissions far from home while opening beds and reducing transfer times to CSCs.
Inclisiran in Patients with CKD
Landmesser, Ulf, Ray, Kausik K., Raal, Frederick J. , Conde, Lorena Garcia , Han, Jackie , Koenig, Wolfgang, Leiter, L., Schwartz, Gregory G. , Wright, R. Scott, Investigators, on behalf of the KCHF Study, Köenig, Wolfgang , Wright, R. Scott , Ray, Kausik K. , Leiter, Lawrence A. , Landmesser, Ulf , Ray, Kausik K , Koenig, Wolfgang , Leiter, Lawrence A , Wright, R Scott , Raal, Frederick J

Mayo Clinic

Journal of the American Society of Nephrology | January 28, 2026 | Volume: 37 | Issue: 7 | Pages: 1497-1506

10.1681/asn.0000001006 | PMID 41604274 Get It

Key Points Inclisiran for LDL cholesterol reduction was analyzed post hoc in patients with CKD. Mean percentage LDL cholesterol reduction from baseline was around 50% regardless of eGFR in phase 3 trials. Inclisiran showed sustained and effective LDL cholesterol–lowering in patients across various levels of eGFR values, without new safety findings. Background Lowering LDL cholesterol reduces the risk of atherosclerotic cardiovascular disease in patients with CKD. The efficacy and safety of inclisiran versus placebo in patients without and with CKD were investigated in a post hoc pooled analysis of three phase 3 trials (ORION-9, ORION-10, and ORION-11). Methods Patients with heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease or its risk equivalent, and elevated LDL cholesterol were randomized 1:1 to subcutaneous inclisiran or placebo on days 1 and 90 and every 6 months thereafter for 540 days. Patients were stratified based on baseline eGFR (by CKD Epidemiology Collaboration equation): ≥90, 60 to <90, 45 to <60, and 15 to <45 ml/min per 1.73 m 2 . Coprimary end points were percentage change in LDL cholesterol at day 510 and time-adjusted percentage change after day 90 and through day 540. Safety was also evaluated. Results Of 3660 patients, 1610 (44%) had eGFR ≥90, 1608 (44%) 60 to <90, 300 (8%) 45 to <60, and 142 (4%) 15 to <45 ml/min per 1.73 m 2 . The mean (95% confidence interval) placebo-corrected percentage changes in LDL cholesterol from baseline at day 510 in patients with eGFR ≥90, 60 to <90, 45 to <60, and 15 to <45 ml/min per 1.73 m 2 were −49.9% (−53.2 to −46.6), −51.2% (−54.4 to −48.0), −54.7% (−62.5 to −47.0), and −44.7% (−57.6 to −31.8), respectively ( P < 0.001); the corresponding mean (95% confidence interval) time-adjusted placebo-corrected percentage changes in LDL cholesterol from baseline after day 90 through day 540 were −48.4% (−50.8 to −46.1), −51.8% (−54.2 to −49.4), −55.6% (−61.0 to −50.2), and −50.4% (−59.3 to −41.5; each P < 0.001). Significant decreases in total cholesterol, apolipoprotein B, non-HDL cholesterol, and lipoprotein(a) occurred in all eGFR groups. Inclisiran was well tolerated without new safety findings. Conclusions Inclisiran demonstrated sustained and effective LDL cholesterol reduction in patients with or at risk of atherosclerotic cardiovascular disease, regardless of baseline eGFR as low as 15 ml/min per 1.73 m 2 , without new safety findings. Clinical Trial registry name and registration number: ClinicalTrials.gov, ORION-9 (NCT03397121), ORION-10 (NCT03399370), and ORION-11 (NCT03400800).
Model for End-Stage Liver Disease-Lactate and Lactate Clearance in Critically Ill Cirrhosis Patients With Sepsis
Shabbir, Rehma , Garrido-Trevino, Luis , O’Leary, Jacqueline G., Chaudhary, Ashok , Maiwall, Rakhi, Arora, Vinod, Tevethia, Harshvardhan V. , Sarin, Shiv K., Hall, Lauren, Ogola, Gerald O., Kamath, Patrick S., Choudhury, Ashok , O'Leary, Jacqueline G , Maiwall, Rakhi , Sarin, Shiv Kumar , Kamath, Patrick S , O’Leary, Jacqueline G. , Maiwall, Rakhi , Arora, Vinod, Ogola, Gerald , Kamath, Patrick S. , Asrani, Sumeet K.

Mayo Clinic

American Journal of Gastroenterology | January 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000003934 | PMID 41589697 Get It

INTRODUCTION: A Model for End-Stage Liver Disease-lactate (MELD-LA) score is an independent predictor of inpatient mortality and organ failure validated in more than 8,600 patients across diverse settings. However, its utility in sepsis, particularly when combined with lactate clearance (LA clearance), has not been fully evaluated. In this study, we examined the dynamic role of MELD-LA with 24-hour LA clearance as a predictor of 30-day mortality in critically ill patients with cirrhosis and sepsis. METHODS: We analyzed cirrhosis patients with sepsis admitted to the intensive care unit (ICU) in a large US healthcare system (20 hospitals) from 2014 to 2022, examining MELD-LA and LA clearance within 24 hours as predictors of 30-day mortality. We externally validated our findings in the Asian Pacific Association for the Study of the Liver-acute-on-chronic liver failure Research Consortium, a multinational Asian cohort (31 centers) from 2009 to 2019. RESULTS: A total of 3,879 cirrhosis patients with sepsis were admitted to the ICU (43.2% female, 20.5% Hispanic, 12.4% on dialysis; mean initial LA 4.5 mmol/L, MELD 20.8, MELD-LA 17.6). Survivors showed a median lactate change of −1.04 (35% clearance) compared with −0.4 (12%) for nonsurvivors. LA clearance within 24 hours was influenced by the presenting MELD-LA. In the North American cohort, ≥35% LA clearance was associated with improved 30-day survival (odds ratio 0.41, 95% CI 0.31–0.53; P < 0.001). Similarly, in the Asian Pacific Association for the Study of the Liver cohort (n = 1,259), ≥35% clearance was linked to a 60% reduction in mortality (odds ratio 0.42, 95% CI 0.28–0.62; P < 0.001). When stratified by LA clearance, patients with LA clearance of ≥35% had a higher percentage of early administration of resuscitative measures than those with LA clearance of < 10% especially regarding early antibiotic administration (82.5% vs 67.6%; P value <0.001). DISCUSSION: Early reduction in initial LA by one-third predicts 30-day mortality and may indicate treatment response in cirrhosis patients with sepsis in the ICU. Combining MELD-LA and LA clearance early enables better risk stratification and informs management.
Ring Artifact Reduction in Photon Counting CT Using Redundant Sampling and Autocalibration
Hsieh, Scott S., Day, James , Deng, Xinchen, Bazalova-Carter, Magdalena, Bazalova‐Carter, Magdalena , Hsieh, Scott S.

Mayo Clinic

IEEE Transactions on Medical Imaging | January 27, 2026 | Volume: 45 | Issue: 5 | Pages: 2532-2541

10.1109/tmi.2026.3658004 | PMID 41587253 Get It